Can a Multifaceted Intervention Including Motivational

Interviewing Improve Medication Adherence, Quality of Life,

and Mortality Rates in Older Patients Undergoing Coronary

Artery Bypass Surgery A Multicenter, Randomized Controlled

Trial with 18-Month Follow-Up by Lin, Chung-Ying et al.
ORIGINAL RESEARCH ARTICLE
Can a Multifaceted Intervention Including Motivational
Interviewing Improve Medication Adherence, Quality of Life,
and Mortality Rates in Older Patients Undergoing Coronary
Artery Bypass Surgery? A Multicenter, Randomized Controlled
Trial with 18-Month Follow-Up
Chung-Ying Lin1 • Mehdi Yaseri2 • Amir H. Pakpour3,4 • Dan Malm4,5 •
Anders Brostro¨m4 • Bengt Fridlund6 • Andrea Burri7,8 • Thomas L. Webb9
 Springer International Publishing Switzerland 2016
Abstract
Background Patients undergoing coronary artery bypass
graft (CABG) surgery are required to take a complex
regimen of medications for extended periods, and they may
have negative outcomes because they struggle to adhere to
this regimen. Designing effective interventions to promote
medication adherence in this patient group is therefore
important.
Objective The present study aimed to evaluate the long-
term effects of a multifaceted intervention (psycho-edu-
cation, motivational interviewing, and short message ser-
vices) on medication adherence, quality of life (QoL), and
mortality rates in older patients undergoing CABG surgery.
Methods Patients aged over 65 years from 12 centers were
assigned to the intervention (EXP; n = 144) or treatment-
as-usual (TAU; n = 144) groups using cluster randomiza-
tion at center level. Medication adherence was evaluated
using the Medication Adherence Rating Scale (MARS),
pharmacy refill rate, and lipid profile; QoL was evaluated
using Short Form-36. Data were collected at baseline; 3, 6,
and 18 months after intervention. Survival status was fol-
lowed up at 18 months. Multi-level regressions and sur-
vival analyses for hazard ratio (HR) were used for analyses.
Results Compared with patients who received TAU, the
MARS, pharmacy refill rate, and lipid profile of patients in
the EXP group improved 6 months after surgery (p\ 0.01)
and remained so 18 months after surgery (p\ 0.01). QoL
also increased among patients in the EXP group as com-
pared with those who received TAU at 18 months post-
surgery (physical component summary score p = 0.02;
mental component summary score p = 0.04). HR in the
EXP group compared with the TAU group was 0.38
(p = 0.04).
Conclusion The findings suggest that a multifaceted
intervention can improve medication adherence in older
patients undergoing CABG surgery, with these
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improvements being maintained after 18 months. QoL and
survival rates increased as a function of better medication
adherence.
ClinicalTrials.gov NCT02109523.
Key Points
A multifaceted intervention including psycho-
education, motivational interviewing, and short
message services improved medication adherence
among patients aged over 65 years who were
undergoing coronary artery bypass graft (CABG)
surgery.
The effects of the multifaceted intervention on
medication adherence were maintained 18 months
following the intervention.
Quality of life and survival rates improved as a
consequence of increasing medication adherence.
1 Introduction
Coronary artery bypass graft (CABG) surgery is often
considered to be the primary intervention for individuals
with severe coronary artery disease and has been shown to
increase quality of life (QoL) and life expectancy [1–3].
The mortality rate during CABG surgery has declined
[4–8], including among older patients, even those aged
90 years or above [6, 7]. However, although CABG is a
promising surgery for older patients with severe coronary
artery disease, there are some reasons to suspect that older
patients may have more negative outcomes after CABG
surgery than younger patients [9, 10].
Patients undergoing CABG surgery are required to take
a complex regimen of medications over a long period of
time [9]. Therefore, one reason why older patients may
have more negative outcomes is that they struggle to
adhere to this regimen [10]. Some characteristics of the
geriatric population, including hearing difficulties,
impaired cognition, poor manual dexterity and vision, and
low tolerance of the effects of drugs may result in low rates
of adherence [11]. In addition, older patients undergoing
CABG surgery share some of the factors that lead to
noncompliance among younger patients, such as poor
education about the importance and adverse effects of each
medication, polypharmacy (the use of four or more medi-
cations), the need to take multiple doses each day, the cost
of medication, and the incorrect use of medication [12].
Because medication adherence positively influences
outcomes (e.g., decreases functional disability, morbidity,
and mortality) [13, 14], it is important to design interven-
tions that can improve medication adherence among older
patients undergoing CABG surgery.
A meta-analysis of 33 randomized controlled trials of
interventions designed to improve medication adherence
among older patients [15] found that the interventions
incorporating psycho-education, behavioral interventions,
and interventions based on the theory of planned behavior
significantly improved medication adherence (effect size,
d = 0.33) and knowledge about medications (d = 0.48)
relative to control conditions. However, the meta-analysis
defined older patients in a relatively broad way (i.e., as
those older than 60 years). Hence, their results may not
generalize to older populations (i.e., those aged over
65 years); especially as age has been found to influence
medication adherence among people with myocardial
infarction [13]. Also, none of the primary studies focused
on promoting medication adherence among older patients
undergoing CABG surgery; therefore, more evidence is
needed on interventions that can improve medication
adherence for older patients undergoing CABG surgery.
Multifaceted interventions seem to be an appropriate
way to promote medication adherence because many fac-
tors can simultaneously influence the behavior [16, 17]. For
example, a prospective study found that medication coun-
seling accompanied by planning increased medication
adherence among patients with a mean age of 59 years
undergoing CABG surgery [18]. However, given that older
samples (e.g., those aged over 65 years) may have addi-
tional issues that prevent them from successfully adhering
to medications (e.g., further impairments to hearing and
cognition); it is possible that additional intervention com-
ponents are needed to promote medication adherence
among these patients. Therefore, the present research
developed an intervention that consisted of psycho-educa-
tion, motivational interviewing (MI) [19–21] accompanied
by planning, and sending reminders via a short message
service (SMS) [22] in an effort to increase medication
adherence among patients aged over 65 years undergoing
CABG surgery. The intervention also encouraged the
patients’ families to help because family members may
influence medication adherence among patients undergoing
CABG surgery [23], especially in Eastern cultures where
family relationships are particularly valued [24].
In addition to identifying effective ways to promote
medication adherence, it is also important to understand
how and why interventions are effective—that is, to
identify the underlying mechanisms. Multifaceted inter-
ventions likely change relevant cognitions and self-regu-
latory processes that, in turn, lead to changes in the
outcomes of interest (namely, medication adherence).
Based on extant research, it seems likely that patients’
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intentions, behavioral automaticity, levels of action and
coping planning, perceived behavioral control, self-mon-
itoring, beliefs about medicines, and illness perceptions
could all potentially mediate the effects of the interven-
tion on outcomes (i.e., medication adherence, QoL, and
mortality rate). Intentions reflect the direction and
strength of a person’s motivation to perform the relevant
behavior (such as medication adherence in our study)
[18]. Behavioral automaticity reflects whether a patient
engages in a behavior (e.g., taking medication) relatively
automatically; that is, quickly, easily, and without the
need for conscious thought [25]. Action and coping
planning reflect the extent to which patients have identi-
fied obstacles that may prevent them from engaging in a
behavior and made plans specifying how they plan to deal
with these; perceived behavioral control reflects how
competent someone feels in their ability to perform a
behavior [26]. Self-monitoring indicates whether someone
regularly reflects on and monitors his/her behavior and/or
the outcomes of their behavior [27, 28]. Beliefs about
medicines refers to a patient’s beliefs about the necessity
and adverse effects of the medication they take [29], and
illness perceptions indicate how a patient understands his/
her illness [30]. A number of theoretical frameworks
suggest that these social cognitions and self-regulatory
processes affect the likelihood that a person will engage
in a behavior [31–34]. Therefore, we considered that these
factors could potentially mediate the impact of the mul-
tifaceted intervention on behavior (i.e., medication
adherence). Moreover, because QoL and mortality rate are
further outcomes of medication adherence [13, 14],
medication adherence should mediate the effect of the
intervention on QoL and mortality rates.
1.1 Objectives
The present study aimed to evaluate the long-term effects
of a multifaceted intervention (including psycho-education,
MI, and an SMS) on medication adherence (primary out-
come), and QoL and mortality rates (secondary outcomes)
in older patients undergoing CABG surgery. In addition,
we measured a number of relevant social cognitions (e.g.,
strength of intentions to take medication) and self-regula-
tory processes (e.g., action and coping planning) as
potential mediators of the effects of the intervention on
medication adherence.
2 Methods
This trial was registered at ClinicalTrials.gov with the
registration number NCT02109523.
2.1 Design and Study Population
The study adopted an open-label, researcher-blind, ran-
domized controlled design, with two arms. Specifically,
one arm received multifaceted intervention (see Sect. 2.3
for more details); another received treatment as usual
(TAU) (see Sect. 2.5 for more details). Patients were
recruited from multiple centers across Iran (five academic
centers in Tehran, two in Qazvin and Ahvaz each, one in
Semnan, Zanjan, and Tabriz each). Inclusion criteria were
that patients (a) be aged 65 years or above, (b) had
undergone CABG surgery, (c) had the ability to read and
write Persian/Farsi, (d) provided informed consent to par-
ticipate, and (e) had access to a mobile phone. Exclusion
criteria were that patients (a) had already used Dosette
boxes (or similar) to improve medication adherence,
(b) were currently enrolled in another clinical trial, (c) had
significant dysphasia, severe kidney disease (creatinine
clearance \30 mL/min), oxygen-dependent chronic
obstructive pulmonary disease, active hepatitis, significant
hepatic failure, and/or a prior peptic ulcer (platelet count
\150 9 109), (d) were having concomitant surgery,
(e) had a severe cognitive impairment [i.e., Mini Mental
Status Examination (MMSE) score of \20], (f) had a
myocardial infarction within 48 h of surgery, (g) were
allergic to aspirin, (h) abused alcohol or narcotics, (i) re-
ported ongoing bleeding, (j) had a terminal condition or
were deemed unlikely to survive until 6-month follow-up,
(k) were not being responsible for their own medication,
and (l) the CABG was conducted as an emergency surgery.
Patients with poor prognosis (n = 2) and those who had
CABG as an emergency surgery (n = 3) were excluded to
increase the likelihood that we were able to measure rel-
evant outcomes at 18 months. Patients requiring emer-
gency or urgent CABG are at higher risk than those
undergoing CABG electively, and emergency CABG is
typically carried out if serious complications develop after
a heart attack (e.g., shock, life-threatening abnormalities of
the heart rhythm, or rupture of heart tissues); thus, there is
an increased risk of mortality among such patients [9].
Five trained general practitioners assessed each partici-
pant with respect to the aforementioned inclusion and
exclusion criteria, after which all eligible patients were
invited to participate in a group information session in a
seminar room in their respective hospitals. In this session,
the principal investigator and a surgeon explained the aims
of the study and answered any questions that the patients
had. Interested patients were then asked to sign a consent
form and were assigned a unique study identification (ID)
number. Following this, patients completed baseline mea-
sures (n = 288 patients completed this assessment). The
measures were repeated at 6, 12, and 18 months after the
intervention. Ethics approval was obtained from the review
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committees of the different centers and partner institutions
who approved the trial (QUMS.REC.1394.2). The study
was conducted in accordance with the Ottawa Statement,
the Helsinki Declaration, and Good Clinical Practice.
2.2 Randomization and Blinding
In order to minimize contamination and maximize the
efficiency with which the intervention was delivered,
centers were chosen as the units of randomization.
Specifically, the centers were randomly assigned to either
the intervention (EXP) or the TAU groups by an inde-
pendent statistician following a 1:1 scheme using a com-
puter-generated list of random numbers. Six centers were
assigned to the EXP group and six centers were assigned to
the TAU group. Figure 1 shows the flow of patients
through the study.
The sample size needed to detect any effects of the
intervention was calculated based on the primary outcome
measure (self-reported medication adherence). It was esti-
mated that 144 patients would be needed in each group to
detect an effect (difference) = 1 score, with 90% power
and a significance level of 5%, assuming a standard devi-
ation of 1.9 in both groups, design effect of 1.8, and 5%
loss at follow up. Exactly 144 patients were therefore
allocated to each group as suggested by the sample size
calculation.
All researchers responsible for measuring outcomes as
well as statisticians were blinded to the group allocation.
However, it was not possible for patients to be blind to
group allocation because of the use of behavioral inter-
ventions. Therefore, objective measures of medication
adherence such as total cholesterol, high-density lipopro-
tein (HDL), and low-density lipoprotein (LDL) concen-
trations were also evaluated, alongside self-reported rates
of adherence to reduce the likelihood of demand effects.
2.3 Intervention
Patients in the EXP group received a multifaceted inter-
vention that included (a) psycho-education, (b) MI, and
(c) sending reminders via SMS. The intervention began the
first week after the patients were discharged.
2.3.1 Psycho-Education
Patients in the EXP group participated in three weekly
sessions accompanied by at least one family member with
whom they had a close relationship (e.g., their son,
daughter, spouse, brother or sister). The psycho-education
component of the intervention was delivered by cardio-
vascular nurses. The contents and topics of psycho-edu-
cation were discussed and preselected by cardiovascular
nurses as well as cardiologists. The content of the psycho-
education was the same for all patients and delivered
orally. Each session lasted for 1 h and the main purpose
was to provide information about coronary artery disease
and ways of coping with the disease (e.g., the potential
barriers to, and concerns about, coping with the disease). In
addition, patients’ experiences during previous visits, a list
of previous medications and their effects and side effects,
the reasons for previous medication non-adherence, as well
as the reactions and communication between the family
members about the patients’ symptoms were discussed.
2.3.2 Motivational Interviewing (MI)
The patients in the EXP group attended five weekly ses-
sions of MI that each lasted around 50 min. All sessions
were held in a quiet, private, and comfortable setting inside
the hospitals. The sessions were delivered by five trained
and registered psychologists with experience (more than
100 h) in moderating MI sessions. These psychologists
used several MI techniques that could potentially help the
patients to increase their medication adherence, including
open-ended questions, rolling with resistance, agenda set-
ting, eliciting self-motivational statements, change talk,
and affirmations. Following this, the psychologists high-
lighted factors that might interfere with the patients’ plans
to take their medication (also called action planning) and
asked the patients to anticipate situations in which they
might struggle to take their medication along with possible
strategies that they might use to overcome these barriers
(also called coping planning) [18]. At the end of the ses-
sion, patients were asked to put the form on which they had
written their plan(s) in a place that was easily visible and
accessible for them. Detailed information on the procedure
for the MI sessions is provided in the electronic supple-
mentary material, Table S1.
2.3.3 Reminders via SMS
Four reminders were sent to patients on a monthly basis via
text messages. The content of the messages differed each
month as follows: (1) ‘‘The only way to improve your
health is regular adherence to your medications;’’ (2)
‘‘Regular adherence to your medications will greatly help
your recovery process and improve your health;’’ (3) ‘‘The
most important factor for preventing a heart attack is that
you take your medication regularly;’’ and (4) ‘‘Carefully
consider which medication you take on a daily basis.’’
2.4 MI Integrity/Fidelity
In order to assess the quality and integrity of MI, all ses-
sions were audiotaped. To evaluate integrity, the
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Motivational Interviewing Treatment Integrity (MITI)
scale 3.1.1 was used [35]. The MITI is a widely used
measure of competences in MI. It normally makes use of a
20-min segment of each MI session and evaluates this
segment based on global scores and behavior counts (two
components of the MITI) to capture treatment fidelity.
Twenty percent of the audiotaped sessions were selected
randomly for evaluation by an independent/external coder.
The global scores comprise five global ratings including
evocation, collaboration, autonomy/support, direction, and
empathy. The behavior counts include providing informa-
tion, asking open- and closed-ended questions, providing
simple and complex reflections, and making other state-
ments categorized as MI adherent or not. In addition to the
abovementioned components, five summary scores (i.e.,
each domain of the global ratings: evocation, collaboration,
autonomy/support, direction, and empathy) were also
computed to provide a more concise measure of
competence.
Table S2 in the electronic supplementary material
provides the global measures, behavior counts, and
summary scores of the MITI. All of the facilitators who
delivered the MI were competent, according to this
measure. Specifically, the means of global measures were
between 3.61 and 4.59, and the mean percentage of
facilitators who were MI adherent was 93.12. Most means
were slightly below competency, but above beginning
proficiency.
2.5 Treatment as Usual
Patients allocated to the TAU group received the advice
commonly given by surgeons on coronary artery disease
and the CABG procedure, along with information on the
importance of healthy diet and nutrition. Patients in the
TAU group were further informed about the importance of
medication adherence and encouraged to regularly take
their medications, as well as being reminded of the nega-
tive consequences of nonadherence. Providing this infor-
mation took approximately 30 min and took place in a
room in the respective hospitals before the patients’
discharge.
Assessed for eligibility (n = 462)
in 12 centers
Excluded (n = 174)
♦Did not meet inclusion criteria (n = 123): 
 Drug or alcohol misuse disorders (n = 12) 
 Concomitant surgery (n = 21) 
MMSE < 20 (n = 43) 
 Severe kidney disease (n = 14)
 Not responsible for taking own medication (n = 
28)
Emergency CABG surgery and poor prognosis
(n = 5) 
♦Declined to participate (n = 42) 
♦Lost contact (n = 9) 
Analysed (intention to treat) (n = 144)
♦Excluded from analysis (n = 0)
Lost to follow-up (n = 24)
♦Died (n = 16) 
♦Moved away (n = 6) 
♦Refused (n = 2)
Allocated to treatment as usual 6 centers (n = 144)
♦Received allocated intervention (n = 144)
♦Did not receive allocated intervention (n = 0)
Lost to follow-up (n = 11)
♦Died (n = 6)
♦Moved away (n = 5) 
Allocated to intervention 6 centers (n = 144)
♦Received allocated intervention (n = 144)
♦Did not receive allocated intervention (n = 0)
Analysed (intention to treat) (n = 144)
♦Excluded from analysis (n = 0)
Allocation
Analysis
Follow-up
Cluster randomized at
center level (12 centers)
(n = 288)
Enrollment
Fig. 1 Flow diagram for random assignment of patients in the study. CABG coronary artery bypass graft, MMSE Mini Mental Status
Examination
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2.6 Outcomes
All outcomes were measured at baseline (before the
intervention), and then 6, 12, and 18 months post-surgery.
Detailed information on each of the measures is described
below. The measures of intentions, action and coping
planning, perceived behavioral control, and self-monitoring
were based on similar measures used in previous research
[18, 25–30], but were adapted so as to be relevant for
Iranian patients undergoing CABG.
2.6.1 Medication Adherence Rating Scale
The Medication Adherence Rating Scale (MARS) is a short
self-report scale measuring medication adherence that
consists of five items which patients are asked to respond to
on a 5-point Likert scale (from 1: always to 5: never) [36].
Scores range from 5 to 25 with higher scores indicating
better medication adherence [18]. The Persian version of
the MARS in the current study proved internally consistent
(Cronbach’s a = 0.89).
2.6.2 Pharmacy Refill Rate
The pharmacy refill rate was defined as the number of days
on which medications were dispensed to the patient during
the study period, divided by the total number of days in the
study period. This figure was then multiplied by 100 to give
a percentage. All related information was collected
monthly from 22 pharmacies in six cities and included the
total number of pills prescribed along with the dates of
each prescription. We assessed the cardiovascular medi-
cation adjusted for inpatient days and medication refills
prior to enrollment date as well as information registered at
6 and 12 months’ follow-up on change in prescriptions.
2.6.3 Lipid Profile
Serum lipid profiles were determined for all patients by
taking 5 mL of venous blood after overnight fasting. Total
cholesterol, triglycerides and high-density lipoprotein-c-
holesterol (HDL-C) concentrations were determined by the
enzymatic colorimetric method. Low-density lipoprotein-
cholesterol (LDL-C) concentrations, as well as serum total
cholesterol, triglycerides and HDL-C concentrations were
calculated using the Friedewald formula.
2.6.4 Intentions
Patients completed a short (5-item) questionnaire designed
to measure their intentions to take medication, with items
(e.g., ‘‘I intend to regularly take medicine in the future’’)
being responded to on a 5-point Likert-type scale (from 1:
completely disagree to 5: completely agree) [18]. The
measure of intentions showed satisfactory internal consis-
tency in this study (Cronbach’s a = 0.90).
2.6.5 Self-Report Behavioral Automaticity Index
The Self-Report Behavioral Automaticity Index (SRBAI)
measures the extent to which a particular behavior (e.g.,
taking medication) is automatic for an individual [25]. The
SRBAI consists of four statements that begin with ‘‘Be-
havior X is something…’’, followed by different descrip-
tions, such as ‘‘I do automatically;’’ ‘‘I do without having to
consciously remember;’’ ‘‘I do without thinking;’’ and ‘‘I
start doing before I realize I am doing it.’’ Patients are
asked to rate the extent to which they agree with each of
the statements on a 5-point Likert-type scale (from 1:
disagree to 5: agree), and items were summed. The Persian
version of the SRBAI was found to be highly reliable in
this study (Cronbach’s a = 0.91).
2.6.6 Action and Coping Planning
Four items were used to measure action planning: ‘‘I have
made a detailed plan regarding when/where/how often/how
to take medication.’’ Another four items were used to
measure coping planning. Patients were provided with the
stem ‘‘I have made a detailed plan regarding…’’ followed
by four different endings: ‘‘…what to do if something
interferes;’’ ‘‘…what to do if I forgot it;’’ ‘‘…how to
motivate myself if I don’t feel like it;’’ ‘‘…how to prevent
being distracted’’ [26]. All items were rated on a 5-point
Likert-type scale (1: completely disagree to 5: completely
agree) and both the measures of action planning (Cron-
bach’s a = 0.93) and coping planning (Cronbach’s
a = 0.91) proved internally consistent.
2.6.7 Perceived Behavioral Control
Perceived behavioral control (PBC) was measured with
four items, to which patients responded on 5-point Likert-
type scales. Items included ‘‘For me to take regular med-
ication in the future is…’’ (1: difficult to 5: easy) and ‘‘It is
up to me to take regular medication’’ (1: strongly disagree
to 5: strongly agree) [26]. The measure of PBC proved
internally consistent in this study (Cronbach’s a = 0.93).
2.6.8 Self-Monitoring
Self-monitoring was measured using three items on a scale
that ranged from 1 (strongly disagree) to 5 (strongly agree).
Each item consisted of a main sentence: ‘‘During the last
month, I have consistently monitored…’’ with ending
variations being ‘‘…when to take medications,’’ ‘‘…how
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often to take medications,’’ and ‘‘…how to take medica-
tions’’ [27]. The internal consistency of self-monitoring in
the present study was acceptable (Cronbach’s a = 0.82).
2.6.9 Beliefs About Medicines
Patients’ beliefs about medication were measured using the
Beliefs about Medicines Questionnaire (BMQ). Although
the BMQ has specific and general sections, only the
specific section, which is thought to be associated with
adherence, was used in the present study [26]. The BMQ-
specific reflects beliefs in two domains—necessity and
concerns—and patients are asked to respond to statements
reflecting each (e.g., ‘‘My health in the future will depend
on my medication’’ [necessity] and ‘‘My medication dis-
rupts my life’’ [concerns]) on a 5-point Likert-type scale
(from 1: strongly disagree to 5: strongly agree). Scores on
each domain can range from 5 to 25 with higher scores
representing more worry about taking medicine. A study
with an Iranian sample with diabetes used the Persian
version of BMQ, and showed satisfactory psychometric
properties [29]. The internal consistency of the BMQ-Ne-
cessity and BMQ-Concerns in the present study were
Cronbach’s a = 0.83 and Cronbach’s a = 0.85,
respectively.
2.6.10 Brief Illness Perception Questionnaire
The Brief Illness Perception Questionnaire (BIPQ) consists
of nine items that assess illness perceptions in the follow-
ing areas: identity, consequences, timeline, personal con-
trol, treatment control, concern, understanding, illness
comprehensibility, and emotional representations [30].
Each item is rated on an 11-point Likert scale, where a
higher score represents a higher level of illness perception.
We used the total score (i.e., summing responses across
each of the nine items), which represents the degree to
which the illness is perceived as threatening or benign [30].
The internal consistency of the BIPQ in the present study
was acceptable (Cronbach’s a = 0.86).
2.6.11 Health-Related Quality of Life: Short Form-36
The health-related QoL Short Form-36 (SF-36) includes 36
items, measuring both physical [physical component
summary (PCS); sample item: ‘‘In general, would you say
your health is…’’] and mental (mental component sum-
mary [MCS]; sample item: ‘‘Have you felt calm and
peaceful?’’) health. The scores were converted into a 0–100
scale, with higher scores indicating better QoL [37, 38].
The SF-36 has been translated into Persian and has been
validated in a sample of Iranian hemodialysis patients
showing satisfactory psychometric properties [39]. The
internal consistencies of SF-36 subscales in the present
study were acceptable and ranged from Cronbach’s
a = 0.74 to Cronbach’s a = 0.93.
2.7 Statistical Analysis
Background information, clinical characteristics, and all
outcome measures are described using means and standard
deviations (SD) for continuous variables and frequency
and/or percentages (%) for categorical variables. Multilevel
linear mixed models were used to investigate the efficacy
of the intervention taking into account the hierarchical
nature of the data (i.e., that the patients were clustered in
different centers) and repeated measures (i.e., that a num-
ber of outcomes were measured at several time points).
Intention to treat (ITT) analysis was used, such that out-
comes among all patients allocated to the groups were
analyzed, whether they completed the intervention or not.
We used three levels of analysis (repeated measures as the
first, patients as the second, and centers as the third levels)
with a restricted iterative generalized least square (RIGLS)
estimation. This RIGLS computes unbiased estimates of
the random parameters. In addition, we used univariate
multilevel analyses to investigate the effects of potential
confounding variables including age, education, family
income, and body mass index. Confounding variables with
a p value \0.20 were controlled for in the multivariate
models. Consequently, each model was adjusted for the
following potential confounding variables: age, sex,
Charlson comorbidity index, and body mass index.
Potential mediators of the relationship between the
intervention and medication adherence and between the
intervention and QoL were examined using Sobel tests.
Finally, survival analyses accounting for cluster effects of
the hospitals were performed, with the cluster effects of
centers being adjusted. All tests were two-tailed using a
significance level of\0.05. The Benjamini and Hochberg
false discovery rate was used to adjust p values for multiple
comparisons where appropriate. Multilevel linear mixed
modeling was conducted using MLwiN 2.27 software.
Survival analyses were performed using the survival
package in R (R Core Team 2014).
3 Results
After screening a total of 462 patients, 288 patients from 12
centers were eligible to participate in the study and the
centers were randomly assigned to either the TAU or the
EXP groups (Fig. 1). Thirty-five patients in the two groups
dropped out during treatment. Table 1 summarizes the
baseline and clinical characteristics of the two groups. The
mean age of patients in the TAU group was 75.23 (SD
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5.82) years and 74.32 (SD 5.26) years for the EXP group
and nearly two-thirds of the patients were male (65.3% in
TAU and 67.4% in EXP).
The descriptive statistics for medication adherence (in-
cluding the MARS, objective pharmacy refill rate, and
serum level of lipid profile), beliefs about medication, and
QoL across the 18 months are reported in Table 2. Overall,
patients in the EXP group showed better medication
adherence after 6 months compared with patients in the
TAU group, as indicated by the MARS (baseline:
7.68 ± 2.45 in EXP and 7.62 ± 2.76 in TAU; 6 months:
13.67 ± 2.80 in EXP and 7.69 in TAU), pharmacy refill
rate (baseline: 62.30 ± 16.22 % in EXP and
61.41 ± 16.30 % in TAU; 6 months: 73.81 ± 18.56 % in
EXP and 63.14 ± 17.21 % in TAU), HDL-C (baseline:
34.54 ± 9.89 % in EXP and 34.42 ± 9.74 % in TAU;
6 months: 42.74 ± 10.41 % in EXP and 34.18 ± 9.38% in
TAU), and LDL-C (baseline: 113.75 ± 33.06 mg/dL in
EXP and 115.20 ± 32.76 mg/dL in TAU; 6 months:
99.26 ± 36.75 mg/dL in EXP and 110.01 ± 35.78 mg/dL
in TAU). Furthermore, medication adherence did not
decrease after 18 months in the EXP group and patients in
this group reported slightly better QoL, including PCS and
MCS, than patients in the TAU group after 6 months.
After considering multicenter and other potential con-
founding factors and effects, the three-level multiple linear
regression models showed that patients in the EXP group
had better medication adherence after 6, 12, and 18 months
compared with patients in the TAU group (see Table 3) as
indicated by the MARS (B = 3.97 at 6 months, 3.83 at
12 months, and 4.24 at 18 months; p\ 0.01), pharmacy
refill rate (B = 9.82 % at 6 months, 10.64 % at 12 months,
and 10.40 % at 18 months; p\ 0.01), total cholesterol
(B = -7.40 mg/dL at 6 months, -8.77 mg/dL at
12 months, and -8.60 mg/dL at 18 months; p\ 0.01),
LDL-C (B = -12.45 mg/dL at 6 months, -13.71 mg/dL
at 12 months, and -13.59 mg/dL at 18 months; p\ 0.01),
HDL-C (B = 8.41 mg/dL at 6 months, 8.71 mg/dL at
12 months, and 8.87 mg/dL at 18 months; p\ 0.01), and
triglycerides (B = -16.83 mg/dL at 6 months,
-18.86 mg/dL at 12 months, and -18.21 mg/dL at
18 months; p\ 0.01).
About 11.1 % of the patients in the TAU group and
4.2 % of the patients in the EXP group had died before the
end of follow-up (Fig. 2). When considering the loss at
follow-up and drop-outs, a Gamma frailty survival model
on the time of death showed that the crude hazard ratio
(HR) in the EXP compared with the TAU group was 0.36
(95% CI 0.14–0.91, p = 0.036). After adjusting for the
effects of age, sex, and number of diseased vessels, this HR
continued to show a lower rate of death in the EXP group
compared with the TAU group (adjusted HR 0.38; 95% CI
0.15–0.97, p = 0.044).
Tables S3 and S4 in the electronic supplementary
material show the effects of intervention on intentions,
perceived behavioral automaticity, self-monitoring, action
and coping planning, beliefs about medicines, illness per-
ceptions, and QoL. Patients in the EXP group reported
better QoL than did patients in the TAU group after
18 months (B = 1.77 and p = 0.02 for PCS; B = 1.68 and
p = 0.04 for MCS). The interactions between group and
time tended to be significant such that patients in the EXP
group (relative to those in the TAU group) tended to have
more positive beliefs about taking medication, reported
stronger intentions to take medication, and had perceptions
of increased control over medication use. They were also
more likely to have formed action and coping plans to
support medication adherence and self-monitor their med-
ication use; and reported that taking medication had
become relatively automatic for them. Social cognitions
and self-regulatory processes all mediated the effects of the
intervention on medication adherence (See Table S5,
electronic supplementary material). An additional media-
tion analysis showed that medication adherence mediated
the effects of the intervention on outcomes such as QoL
and survival rates.
4 Discussion
The present findings suggest that a multifaceted interven-
tion with three components (psycho-education, MI, and
SMS reminders) can improve medication adherence, QoL,
and mortality rates among older patients undergoing
CABG surgery. Specifically, patients who received the
multifaceted intervention program (i.e., patients in the EXP
group) showed increased MARS scores and higher phar-
macy refill rates at 6 and 18 months after surgery. In
contrast, MARS scores and pharmacy refill rates did not
increase among patients who received conventional treat-
ment and information (i.e., among patients in the TAU
group). Other measures used to objectively assess medi-
cation adherence (including total cholesterol, HDL-C,
TDL-C, and triglycerides) supported these conclusions and
showed that patients in the EXP group were in better
physiological health than patients in the TAU group in the
6–18 months after the intervention. In addition to medi-
cation adherence, patients who received the multifaceted
intervention also reported better QoL and had a higher life
expectancy compared with patients in the TAU group.
Previous studies have also reported beneficial effects of
MI on medication adherence, albeit among different sam-
ples than those studied here, such as older people (aged
53–73 years) [40] and people with epilepsy [26]. Further-
more, previous studies attest to the efficacy of combining
medical counseling with planning for promoting
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medication adherence among patients undergoing CABG
[18]. However, although a number of studies have shown
the beneficial effects of such interventions, the current
study combined the intervention components and, perhaps
as a result, seemed to be even more effective in increasing
medication adherence in older patients (d = 2.13 in the
Table 1 Comparison of clinical characteristics between the intervention (EXP) and treatment-as-usual (TAU) groups at baseline
Treatment as usual (n = 144) Intervention (n = 144)
Age, years; median (IQR) 76 (70–80) 75 (69–79)
Years of education; median (IQR) 4 (1–12) 4 (1–12)
Household income, Iranian rialsa; median (IQR) 848.65 (453.40–1295.44) 893.06 (942.88–1286.88)
Body mass index, kg/m2; mean ± SD 28.84 ± 5.57 28.64 ± 4.03
Marital status; n (%)
Single 4 (2.8) 6 (4.2)
Married 90 (62.5) 92 (63.9)
Divorced/widowed 50 (34.7) 46 (31.9)
Sex; n (%)
Male 94 (65.3) 97 (67.4)
Female 50 (34.7) 47 (32.6)
Ejection fraction; mean ± SD 45.23 ± 6.12 44.82 ± 7.02
Cross clamp time, min; mean ± SD 52.42 ± 25.81 54.21 ± 27.62
Cardiopulmonary bypass duration time, min; mean ± SD 96.68 ± 39.42 97.92 ± 40.35
Cardiac risk factors; n (%)
Diabetes mellitus 55 (38.2) 52 (36.1)
Hypertension 107 (74.3) 110 (76.4)
Dyslipidemia 61 (42.4) 52 (36.1)
Myocardial infarction 86 (59.7) 90 (62.5)
Chronic lung disease 17 (11.8) 15 (10.4)
Prior cardiac surgery; n (%) 12 (8.3) 9 (6.2)
Current smoker; n (%) 21 (14.6) 18 (12.5)
No. of major vessels/branches bypassed; n (%)
1 vessel 21 (14.6) 14 (9.7)
2 vessels 49 (34.0) 46 (31.9)
3 vessels 74 (51.4) 84 (58.3)
CCSC; n (%)
I 12 (8.3) 10 (6.9)
II 24 (16.7) 15 (10.4)
III 48 (33.3) 51 (35.4)
IV 60 (41.7) 68 (47.2)
Charlson comorbidity index; n (%)
0 40 (27.8) 36 (25.0)
1–3 79 (54.9) 81 (56.2)
C4 25 (17.4) 27 (18.8)
Medications; n (%)
Aspirin 135 (93.8) 132 (91.7)
Beta blockers 115 (79.9) 122 (84.7)
ACE inhibitors 98 (68.1) 90 (62.5)
Lipid-lowering drugs 105 (72.9) 109 (75.7)
Number of centers 6 6
Number of patients in each center 24 24
ACE angiotensin-converting enzyme, CCSC Canadian Cardiovascular Society Classification, IQR interquartile range, SD standard deviation
a 3500 rials = US$1 (April 2016 values)
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present research; d = 0.30–1.02 in previous studies
[18, 26, 40]). In short, the present findings support the
effects of similar interventions conducted in other popu-
lations [21, 26, 40], such as patients with epilepsy, and
show that MI and counseling can effectively enhance
medication adherence in older individuals [41–44].
The present research also builds on previous studies by
showing that a multifaceted intervention not only increases
medication adherence but, as a result, can improve QoL
and increase life expectancy in older patients receiving
CABG. Interestingly, the effects on QoL were only
observed at 18 months after surgery, compared with the
changes in medication adherence that were observed at
6 months after surgery. However, this is to be expected
given that both previous and the present research show that
QoL is influenced by medication adherence and thus takes
time to change [45–47]. In terms of the effects of the
intervention on survival rates, previous studies have
Table 2 Descriptive statistics for all outcome measures across time in the intervention group (EXP) and the treatment-as-usual (TAU) group
Variable (normal range) Group Mean (SD)
Baseline Month 6 Month 12 Month 18
BMQ-Necessity (5–25) TAU 14.62 (3.22) 14.54 (3.30) 14.41 (2.42) 14.40 (3.07)
EXP 14.37 (2.24) 18.69 (2.49) 18.64 (2.48) 18.53 (2.57)
BMQ-Concerns (5–25) TAU 13.23 (4.05) 13.27 (4.0) 13.31 (4.27) 13.33 (4.12)
EXP 12.92 (3.29) 7.81 (3.22) 6.02 (3.09) 4.78 (3.01)
Perceived behavioral control (1–5) TAU 2.50 (0.93) 2.43 (0.98) 2.41 (0.99) 2.40 (0.93)
EXP 2.49 (0.89) 3.00 (1.10) 2.98 (1.01) 2.99 (1.12)
Intention (1–5) TAU 2.67 (0.65) 2.73 (0.69) 2.70 (0.70) 2.69 (0.69)
EXP 2.72 (0.74) 3.44 (1.03) 3.41 (1.01) 3.42 (1.13)
Self-monitoring (1–5) TAU 1.94 (0.40) 1.92 (0.51) 1.96 (0.75) 1.91 (0.82)
EXP 2.06 (0.54) 2.65 (1.00) 2.67 (1.04) 2.66 (1.02)
Action planning (1–5) TAU 1.93 (0.58) 1.190 (0.52) 1.88 (0.50) 1.86 (0.61)
EXP 1.88 (0.57) 2.73 (1.13) 2.71 (1.30) 2.74 (1.29)
Coping planning (1–5) TAU 1.68 (0.51) 1.64 (0.56) 1.61 (0.52) 1.62 (0.60)
EXP 1.64 (0.54) 2.49 (1.11) 2.48 (1.19) 2.50 (1.26)
SRBAI (1–5) TAU 1.91 (0.80) 1.87 (0.82) 1.86 (0.99) 1.83 (1.01)
EXP 1.86 (0.87) 2.39 (0.94) 2.40 (0.98) 2.40 (1.14)
MARS (5–25) TAU 7.62 (2.76) 7.69 (2.70) 7.71 (2.79) 7.63 (2.88)
EXP 7.68 (2.45) 13.67 (2.80) 13.61 (2.82) 13.70 (2.75)
Illness perception (0–90) TAU 36.43 (11.67) 35.57 (11.66) 36.63 (11.54) 36.67 (11.47)
EXP 37.07 (11.78) 33.93 (12.53) 33.80 (12.72) 33.46 (10.17)
Pharmacy refill rate (0–100) TAU 61.41 (16.30) 63.14 (17.21) 62.03 (18.77) 62.03 (18.77)
EXP 62.30 (16.22) 73.81 (18.56) 73.48 (18.44) 73.24 (15.33)
Quality of life: PCS (0–100) TAU 46.07 (11.66) 48.23 (11.70) 47.88 (12.05) 47.08 (10.10)
EXP 46.88 (10.68) 50.04 (12.41) 50.29 (12.69) 49.93 (9.65)
Quality of life: MCS (0–100) TAU 43.42 (12.76) 46.77 (11.41) 46.82 (11.33) 46.48 (10.35)
EXP 44.92 (10.14) 49.39 (12.60) 49.76 (10.93) 49.69 (11.84)
Total cholesterol concentration (mg/dL) TAU 182.90 (38.69) 180.76 (33.89) 180.71 (33.51) 180.53 (35.81)
EXP 181.85 (39.00) 172.32 (40.71) 170.92 (32.12) 171 (32.00)
HDL-C (mg/dL) TAU 34.42 (9.74) 34.18 (9.38) 33.88 (10.52) 33.52 (8.16)
EXP 34.54 (9.89) 42.74 (10.41) 42.63 (11.29) 42.41 (9.31)
LDL-C (mg/dL) TAU 115.20 (32.76) 110.01 (35.78) 113.32 (35.57) 114.51 (35.65)
EXP 113.75 (33.06) 99.26 (36.75) 98.26 (27.32) 98.69 (27.41)
Triglycerides (mg/dL) TAU 166.37 (66.60) 167.07 (65.99) 167.52 (55.43) 165.27 (65.21)
EXP 167.61 (69.38) 151.55 (66.55) 150.13 (58.05) 149.33 (68.90)
BMQ Beliefs about Medicines Questionnaire, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, MARS
Medication Adherence Rating Scale, MCS Mental Component Summary, PCS Physical Component Summary, SRBAI Self-Report Behavioral
Automaticity Index
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demonstrated that psycho-education and MI can reduce
mortality in patients with different diseases [48–50],
including coronary heart diseases. Our results echo such
findings and further support the idea that the combination
of psycho-education and MI can improve survival rates
through medication adherence.
4.1 Strengths and Limitations
There are several strengths to our study. First, an 18-month
follow-up without further intervention was used to investi-
gate the long-term effects of the intervention on medication
adherence and a number of health-related outcomes in
patients undergoing CABG. As such, the findings provide
important insights for clinicians with regards to the long-
term effects of such interventions, not only on medication
adherence but also on patients’ overall health and QoL.
Second, the present study included a variety of objective
outcome measures to assess medication adherence and did
not rely on self-report alone; therefore minimizing social
desirability and reporting biases. Third, robust statistical
analyses were conducted that accounted for potential con-
founding variables. By using multilevel linear mixed mod-
els, shared variance (e.g., accruing from recruiting patients
from the same hospital) were minimized [51].
However, there are also some limitations that need to be
considered when interpreting the findings. First, the effects
of the intervention may not be generalizable to Western
Table 3 Three-level multiple linear regression models predicting medication adherence
Variable MARS Pharmacy refill
rate
Total cholesterol LDL-C HDL-C Triglycerides
B (SE) p value B (SE) p value B (SE) p value B (SE) p value B (SE) p value B (SE) p value
Group (Ref:
TAU)
0.30
(0.66)
0.36 2.37
(2.62)
0.26 -3.30
(7.25)
0.36 -3.01
(5.94)
0.35 15.52
(5.64)
0.01 -4.54
(9.73)
0.36
Time (Ref: baseline)
6 months 0.38
(0.16)
0.02 1.81
(0.66)
0.01 -2.21
(1.34)
0.10 -2.22
(1.29)
0.09 0.12
(0.43)
0.38 -0.61
(1.79)
0.38
12 months 0.30
(0.14)
0.045 0.66
(0.46)
0.14 -2.26
(1.60)
0.15 -1.97
(1.31)
0.13 0.54
(0.40)
0.16 -1.21
(1.94)
0.33
18 months 0.05
(0.16)
0.38 0.91
(0.78)
0.20 -2.45
(1.60)
0.12 -1.79
(1.30)
0.16 0.92
(0.31)
0.01 -1.38
(1.86)
0.30
Group 9 time
EXP vs TAU at
6 months
3.97
(0.22)
<0.01 9.82
(0.93)
<0.01 -7.40
(1.88)
<0.01 -12.45
(1.80)
<0.01 8.41
(0.60)
<0.01 -16.83
(2.52)
<0.01
EXP vs TAU at
12 months
3.83
(0.23)
<0.01 10.64
(0.95)
<0.01 -8.77
(1.92)
<0.01 -13.71
(1.93)
<0.01 8.71
(0.73)
<0.01 -18.86
(2.80)
<0.01
EXP vs TAU at
18 months
4.24
(0.26)
<0.01 10.40
(0.98)
<0.01 -8.60
(1.99)
<0.01 -13.59
(1.78)
<0.01 8.87
(0.60)
<0.01 -18.21
(2.70)
<0.01
Age -0.19
(0.14)
0.17 -0.13
(0.13)
0.25 1.40
(1.41)
0.24 0.61
(1.23)
0.35 -0.92
(0.35)
0.01 0.46
(1.91)
0.39
Sex (Ref:
females)
0.33
(0.47)
0.31 -8.32
(2.58)
<0.01 2.52
(1.63)
0.12 5.16
(3.68)
0.15 0.12
(0.10)
0.20 0.62
(0.86)
0.31
Charlson
comorbidity
index
-0.92
(0.65)
0.15 -1.69
(0.75)
0.03 9.59
(7.22)
0.17 -11.85
(6.91)
0.09 -6.64
(1.49)
<0.01 2.28
(0.98)
0.03
Body mass index -0.06
(0.04)
0.16 -0.31
(0.61)
0.35 3.26
(1.26)
0.01 1.76
(4.01)
0.36 -0.35
(0.19)
0.07 8.37
(0.91)
<0.01
Intercept 11.14
(2.32)
<0.01 55.19
(8.66)
<0.01 164.84
(23.06)
<0.01 11.02
(2.26)
<0.01 15.21
(5.64)
0.01 187.83
(45.75)
<0.01
r^2st (patients) 14.97
(0.96)
<0.01 103.90
(13.19)
<0.01 46.70
(9.18)
<0.01 53.59
(8.41)
<0.01 93.12
(5.98)
<0.01 46.91
(15.61)
<0.01
r^2sc (centers) 3.52
(0.12)
<0.01 32.08
(11.64)
0.01 26.23
(8.58)
<0.01 37.21
(6.81)
<0.01 9.49
(3.88)
0.02 24.92
(16.10)
0.12
EXP intervention group, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, MARS Medication Adherence
Rating Scale, Ref reference group for comparison, SE standard error, TAU treatment as usual group, r^2st the variance at patient level, r^
2
sc the
variance at center level
p values\0.05 are in bold
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countries and cultures, particularly as the present research
incorporated an element of family engagement. Unlike
Western cultures that tend to emphasize individualism [52],
family plays a crucial role for people with a Middle Eastern
cultural background [53]. Second, patients with serious
and/or specific health conditions (e.g., suffering from
cognitive impairment or from a severe kidney disease)
were excluded from the present research. Therefore, the
findings may not generalize to other patients undergoing
CABG who have additional health problems. Further
studies are therefore warranted to investigate the effects of
similar interventions in such groups. Third, because the
present research developed and implemented a multi-
faceted intervention, the individual effects of each com-
ponent cannot be separated. In other words, it is unclear
which of the three components (psycho-education, MI, and
SMS reminders) were effective in promoting medication
adherence, and could potentially be used as individual
components, or whether the outcomes were dependent on a
joint effect. The larger effect size reported in the present
research, relative to other studies that tested the effects of
interventions that only incorporated one or some of these
components, suggest that the multifaceted intervention was
particularly beneficial, but factorial designs that directly
compare interventions with different components are
needed to corroborate this assertion. Lastly, the interven-
tion used in the present research was relatively intensive
and required a substantial time commitment from both the
patients and those delivering the intervention. Although the
findings were promising, further research could evaluate
the cost effectiveness of the intervention relative to, for
example, less complex interventions. Again, a factorial
design would appear to be appropriate for this purpose.
5 Conclusion
The findings of the present study suggest that a multi-
faceted intervention consisting of psycho-educational, MI,
and SMS reminders can promote medication adherence in
older patients undergoing CABG, and that these effects are
maintained 18 months after surgery. The increase in
medication adherence as a function of the intervention also
improved other health-related outcomes. Clinicians may
therefore consider using multifaceted interventions to
improve health and survival rates in older patients under-
going CABG.
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